Description: Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead program is atrasentan, an investigational Phase 3-ready endothelin receptor antagonist for the treatment of IgA nephropathy and other primary glomerular diseases. Its product candidates include BION-1301, an investigational anti-APRIL monoclonal antibody is being evaluated in a Phase 1b trial for IgA nephropathy; and CHK-336, a preclinical development candidate for an undisclosed ultra-orphan kidney disease, as well as research programs for other rare, severe chronic kidney diseases, including polycystic kidney disease. Chinook Therapeutics, Inc. is based in Seattle, Washington.
Home Page: www.chinooktx.com
KDNY Technical Analysis
400 Fairview Avenue North
Seattle,
WA
98109
United States
Phone:
206 485 7241
Officers
| Name | Title |
|---|---|
| Mr. Eric L. Dobmeier J.D. | Pres, CEO & Director |
| Mr. Tom Frohlich | Chief Operating Officer |
| Mr. Andrew James King D.V.M., Ph.D. | Chief Scientific Officer |
| Mr. Eric H. Bjerkholt M.B.A. | Chief Financial Officer |
| Ms. Noopur Batsha Liffick | VP of Investor Relations & Corp. Communications |
| Mr. Kirk D. Schumacher J.D. | Sr. VP & Gen. Counsel |
| Ms. Jodi Jamieson | VP of HR |
| Dr. Alan Glicklich M.D. | Exec. Officer |
| Ms. Delphine Imbert Ph.D. | Sr. VP of CMC & Technical Operations |
| Dr. Charlotte Jones-Burton M.D., M.S. | Sr. VP of Product Devel. & Strategy |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 3.0567 |
| Price-to-Sales TTM: | 27.9034 |
| IPO Date: | 2015-04-15 |
| Fiscal Year End: | December |
| Full Time Employees: | 138 |